Schizophrenia Treatment Adherence Investigation (STAI)

Clinical Audit and Feedback Program to Determine Risk for Medication Adherence in Outpatients Diagnosed With Schizophrenia in Australia

The primary objective of this treatment review and feedback program is to quantify the risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia.

The primary objective of this treatment review and feedback program is to quantify the risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia. Observational study - no study drug administered

Inclusion Criteria:

• Clinical diagnosis of schizophrenia or schizoaffective disorder according to DSM-IV
• Currently treated in an outpatient clinic
• Able to provide informed consent
• Concurrent enrolment in clinical trials is acceptable
• Have completed all questions on the Drug Attitude Inventory (DAI-10) and Medication Adherence Rating Scale (MARS) survey

Exclusion Criteria:

• N/A